ArticleMolecular therapy. Advances2026
Autofluorescence imaging reveals the impact of cryopreservation on T cell metabolism and activation response.
Article in Molecular therapy. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
10 authors.
Funding
Abstract
Cryopreservation or the process of freezing cells is a cornerstone of most cell therapy protocols. Optimization of cryopreservation protocols and cryoprotectant agents to improve cell viability and functionality is under further investigation. However, the impact of cryopreservation on cellular metabolism and function immediately post-thaw is not fully understood. Here, we used label-free, non-invasive optical metabolic imaging (OMI) of NAD(P)H and FAD to characterize the activation response of frozen T cells from healthy donors and lymphoma patients post-thaw. Using OMI, we identified significant metabolic shift, along with delayed and diminished activation response, in healthy donor T cells throughout the first 4.5 h upon thawing. In cryopreserved peripheral T cells from lymphoma patients in our bispecific CD20/CD19 CAR T clinical trial, OMI could identify early metabolic stress and allowed gating of metabolically fit cells associated with post-thaw viability. Notably, in our pilot study involving four patients, metabolically fit T cells from complete responders exhibited metabolic responses to activating stimuli within the first 4.5 h post-thaw. Overall, our findings suggest that 4-5 h post-thaw is a critical time window to assess the impact of cryopreservation and thawing, supporting the potential of OMI to optimize cryopreservation protocols and evaluate patient T cell quality for cell therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.